BPC-157 and WADA Bans: What Triathletes Need to Know About Peptide Doping Rules

A record-breaking ultra-runner's casual podcast admission about using an unapproved peptide has ignited a firestorm in endurance sports—and triathlon may be next. The question isn't whether BPC-157 works. It's whether we should ban it at all, who gets to make that call, and what it means for the hundreds of thousands of age-group athletes who train through chronic injury every single season.

If you've ever wondered whether that peptide injection your doctor mentioned could get you banned from your next race, this guide is for you.

What Is BPC-157—and Why Is It Banned?

The Peptide Itself

BPC-157 is a synthetic pentadecapeptide—a chain of 15 amino acids—originally isolated from gastric juice, the stuff inside your stomach lining. That's about where the certainty ends.

As of a 2025 systematic review, there has been precisely one human study on BPC-157, involving just 12 participants. The remaining 35 studies were performed on animals. That's it. For a substance generating this much buzz in endurance sports communities from São Paulo to Seattle, the scientific foundation is remarkably thin.

Animal research does show promise, though. Studies suggest BPC-157 produces improved outcomes in muscle, tendon, ligament, and bone injury models. According to Dr. Christopher Raffo of Maryland Orthopedic Specialists, the peptide may work through multiple biological pathways:

• Promoting new blood vessel growth
• Boosting collagen production
• Reducing inflammation
• Supporting muscle and nerve function

Dr. Raffo notes that these combined effects are particularly intriguing for orthopedics because many musculoskeletal injuries—Achilles tendon ruptures, rotator cuff tears, chronic tendinopathies—occur in precisely those areas where blood flow is limited and healing is frustratingly slow.

This is exactly the kind of injury profile that plagues triathletes. Which is why this debate is coming for our sport whether we're ready or not.

Why WADA Bans It Automatically

BPC-157 is not FDA-approved. You can buy it online, labeled "for research purposes only," but there is no standardization, no quality control, and unknown long-term side effects. That regulatory gray area is precisely why WADA classifies it under S-0: Non-Approved Substances—a catch-all category that prohibits any substance lacking current approval from any governmental health authority for human therapeutic use.

"Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times."

The bottom line: No FDA approval = automatic ban, full stop. Medical intent doesn't change the classification. Ignorance of the rule doesn't either.

The Ultra-Running Cases That Started It All

Mike McKnight's Herniated Disc

The controversy exploded in July 2026 when ultra-runner Mike McKnight appeared on Cam Hanes' podcast and disclosed he had used BPC-157 to avoid back surgery. McKnight is no weekend warrior—he set a course record at the Arizona Monster 300 in spring 2026 and finished 13th at Cocodona 250 in May, having previously won and placed second at that same race in 2022 and 2023.

His injury came from an unlikely source: slipping on laundry detergent after Cocodona 250. He had surgery scheduled when friends pointed him toward the peptide.

"A nurse came to my house, taught me about the benefits of it, and recommended how much to take each day," McKnight wrote on Instagram. "I followed her advice and saw major improvements by the end of the first week. By the time my surgery date had arrived, I felt almost 100% better. I called the surgeon and canceled my surgery."

"I'm also not going to sit here and say I regret my decision. This decision kept me from having to have back surgery. This decision made it so I could walk and start doing something that has been a part of my life for almost 15 years. If being honest about this decision brings me hate, I'll move on with my life. If this makes it so I'm banned from every race under the sun, I'll wake up tomorrow and every day after that and go for a fun run."

That kind of unrepentant honesty is both admirable and, from an anti-doping standpoint, a textbook admission of a violation.

Cam Hanes' Broken Foot

Cam Hanes had already publicly acknowledged using BPC-157 before McKnight's appearance amplified the conversation. The 58-year-old bowhunter and age-group runner used the peptide to avoid surgery on a broken foot—exactly the type of injury Dr. Raffo identifies as a candidate for potential peptide benefit.

Hanes is no contender for overall victory. At the Eugene Marathon in April 2026, he ran a 13-minute personal best of 2:39:11, finishing 70th overall—but winning his age group. When challenged by elite ultra-runner Sage Canaday about his knowledge of anti-doping rules, Hanes essentially shrugged:

"I have no idea if I could pass a drug test? I don't have any clue what they even test for? I'm a bowhunter. I run to get in shape for that. You're the elite runner. It's your job to know the rules."

That response captured what makes this case so thorny: Hanes has 1.8 million Instagram followers, a significant platform, and a recent age-group championship—but genuinely sees himself as a recreational participant.

The Three-Camp Divide

The ultra-running community fractured into three distinct positions:

Camp 1 — Strict Enforcers: Led by Sage Canaday, this group argues that rules are rules. Both athletes admitted use, both should face bans. Canaday went further, posting a video to Instagram showing how to locate and read anti-doping rules—a pointed rebuke to claims of ignorance.

Camp 2 — Medical Benefit Advocates: This group centers on the fact that both McKnight and Hanes used BPC-157 therapeutically, not for performance enhancement. Their argument: medical intent should matter, and banning legitimate injury treatment is ethically questionable.

Camp 3 — Status Differentiators: Writer Kilian Korth articulated a third position—that McKnight (a professional racer and coach) and Hanes (an age-group competitor) should face different consequences. Professional athletes carry greater responsibility and have more resources to know the rules.

None of these camps is arguing that BPC-157 is not banned. They're arguing about whether it should be banned—and who should be held accountable. That's a much harder conversation.

The Testing Disparity Nobody Is Talking About

Ultra-Running's Enforcement Vacuum

Here's a number that puts the debate in sharp relief: since 2023, USADA has performed a total of 175 tests on Mountain, Ultra, and Trail athletes. During that same period, triathlon athletes received approximately 875 USADA tests—five times as many.

Ryan Heisler, Slowtwitch's editor who has covered anti-doping in endurance sports for over seven years, describes ultra-running's enforcement as "a patchwork of efforts." That's a polite way of saying it barely functions as a deterrent at all.

When the perceived risk of getting caught is effectively zero, athletes—especially those already inclined to push limits—will push limits. The McKnight and Hanes admissions may be the visible tip of a much larger iceberg.

The Iowa Cross Country Case

This isn't isolated to professional ultra-running, either. The Slowtwitch forum surfaced a case involving multiple Iowa cross country athletes who allegedly used BPC-157. One athlete reportedly dropped down to Division III competition and won a championship—prompting the rest of the podium to walk off in protest.

Peptide use is spreading across endurance sports. It isn't a fringe phenomenon confined to extreme-distance racing.

Is Triathlon Already Affected?

Signs the Problem Has Arrived

Triathlon has higher testing rates than ultra-running, but that doesn't mean it's immune. At a long-distance triathlon trade show in Ottawa in July 2026, a popup tent was openly advertising BPC-157 infusions alongside testosterone replacement therapy. When one attendee told the vendor the substance was banned, the vendor's response was telling: the vendor confused legal to purchase with legal to use in competition—a distinction that many age-group athletes don't understand either.

Informal networks—especially those connected to regions where regulatory oversight is lighter—are already moving this substance through endurance sport communities across Mexico and Latin America, where athletes report persistent injuries healing remarkably fast after peptide use.

Why Triathlon Is Particularly Vulnerable

Several factors make triathlon a natural target for peptide adoption:

• Higher barrier to entry attracts wealthier athletes with access to experimental treatments
• Chronic injury prevalence (shoulder, knee, hip, Achilles) creates medical motivation
• Age-group gray zone offers high competition stakes with lower perceived testing scrutiny
• Vendor access at race expos, as the Ottawa example illustrates

"AG elite is the perfect place to stay to satisfy the ego and evade policing of PEDs and drafting."

Competitive age-groupers targeting World Championship slots occupy a strange middle ground—competing at a genuinely high level while remaining largely below the testing radar. Coach tilburydavis put it bluntly: peptide use and even micro-dosing anti-aging meds is already widespread, with short half-lives making detection impractical. Coach Joel Filliol's observation cuts to the core: long-distance anti-doping has become an IQ test.

A Framework for Who Gets Held to What Standard

This is where the debate gets genuinely difficult—and where Heisler's framework offers a useful structure.

Tier 1: Professional and Elite License Holders

These athletes compete for prize money, sponsorships, or elite status. They should be held to the absolute strictest interpretation of the WADA Code—no exceptions, no ignorance defense.

The WADA Code was created specifically for this tier, born directly from the Festina Affair at the 1998 Tour de France, when systematic doping at the highest level of professional cycling forced the creation of a unified anti-doping framework. When McKnight, a professional racer and coach, says he didn't know BPC-157 was banned, that explanation doesn't hold. He has to know.

Tier 2: Competitive Age-Group Athletes

These are athletes winning local races, earning World Championship slots, or on a pathway toward professional status. They compete nationally and internationally and should be held to elevated standards—but the current system doesn't always make that explicit.

Heisler has long advocated for restoring an opt-in mechanism at race registration: checking a box that explicitly commits an athlete to full WADA Code compliance in exchange for World Championship qualification. That function was turned off in the registration process roughly 15 years ago, and its absence creates a loophole that serious competitive age-groupers can—and apparently do—exploit.

Cam Hanes lands here. His Eugene Marathon performance and his enormous social media platform elevate him above purely recreational status, regardless of how he personally identifies.

Tier 3: Participatory and Recreational Athletes

These are your 13-to-14-hour long-distance triathlon finishers. The bucket-list athletes. The people who fund a lot of our sport's existence. They're also the ones most likely to take McKnight's position—this healed me, it was medical treatment, sport consequences be damned.

There's a real question about whether enforcing unapproved substance bans against someone who finishes in the final wave of a local triathlon serves any legitimate competitive fairness interest. Heisler is sympathetic to loosening some rules for recreational athletes—rules on running with your family, or on drafting, can be loosened for purely recreational athletes without ruining the integrity of the sport.

But he draws a firm line at experimental treatments: loosening drafting rules for recreational athletes doesn't create safety or medical risks. Normalizing the use of unapproved biological compounds with unknown long-term effects is a different matter entirely. The prudent course is to press pause on BPC-157 until human trials trend toward regulatory approval.

What Athletes Should Actually Do Right Now

If You're a Professional or Elite-Licensed Athlete

• Know the WADA Prohibited List cold. Ignorance is not a defense.
• Assume any unapproved substance is banned until you've verified otherwise.
• Consult anti-doping organizations—not just your physician—before beginning any new treatment.
• Understand that injury recovery may simply take longer than alternatives allow.

If You're a Competitive Age-Grouper

• If you're targeting a World Championship slot, treat yourself as Tier 1. The rules don't care how you identify.
• Check the WADA Prohibited List before starting any supplement protocol or medical treatment.
• Remind yourself: legal to buy does not equal legal to use in competition. That popup tent in Ottawa was selling a banned substance.
• Ask your doctor specifically about anti-doping implications before accepting any treatment recommendation.

If You're a Recreational Athlete

• Know your local race rules and understand that WADA Code applies to all sanctioned events.
• If you choose to use unapproved treatments for medical reasons, recognize that competing in sanctioned races while doing so may constitute a violation.
• Weigh personal health benefits against competition eligibility—and be honest with yourself about which tier you actually compete in.

The Bigger Picture

The BPC-157 debate isn't really about one peptide. It's about the widening gap between what athletes can do medically and what the sport allows them to do competitively. As experimental treatments become cheaper, more accessible, and more culturally normalized—particularly in markets across Latin America and other regions with lighter regulatory oversight—that gap is going to keep growing.

"If we look at even simple examples of cheating in society, e.g. in high pressure, high reward environments such as Ivy League schools and plagiarism, studies have shown 1 in 10 exert some element of cheating. Why would sport be any different?" — Former WADA Director David Howman

What needs to happen:

• Ultra-running needs anti-doping resources and consistency that approach what triathlon currently has
• Triathlon should begin preparing governance frameworks for peptide use among age-groupers before it becomes widespread
• WADA should clarify the TUE pathway for therapeutic peptides as human research advances
• Race organizers should restore explicit opt-in anti-doping agreements for World Championship qualification
• The medical community should accelerate BPC-157 human trials—if efficacy is proven, a clear regulatory approval pathway should be pursued

For now, the rule is clear: BPC-157 is banned. McKnight and Hanes both violated the Code. The question of whether the Code itself needs to evolve—and how enforcement should be tiered by athlete status—is a debate that's just getting started. And triathlon is next.

Source: Slowtwitch — A Peptide Debate Is Rocking Ultra-Running. Is Triathlon Next?